Who are Valsartan (-based therapy) arm's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): olmesartan medoxomil and a diuretic, Amosartan® tab, Cozaar®, Low dose losartan, irbesartan and irbesartan-hydrochlorothiazide, Placebo to Telmisartan.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/valsartan-based-therapy-arm.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

Valsartan (-based therapy) arm — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Valsartan (-based therapy) arm (Valsartan (-based therapy) arm) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor blocker (ARB). Area: Cardiovascular.

marketed Angiotensin II receptor blocker (ARB) AT1 receptor (Angiotensin II type 1 receptor) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Valsartan (-based therapy) arm (Valsartan (-based therapy) arm) — Hippocration General Hospital. Valsartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release to lower blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Valsartan (-based therapy) arm TARGET	Valsartan (-based therapy) arm	Hippocration General Hospital	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (Angiotensin II type 1 receptor)
olmesartan medoxomil and a diuretic	olmesartan medoxomil and a diuretic	Daiichi Sankyo Co., Ltd.	marketed	Angiotensin II receptor blocker (ARB) + diuretic combination	AT1 receptor (angiotensin II type 1 receptor)
Amosartan® tab	Amosartan® tab	Hanmi Pharmaceutical Company Limited	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (angiotensin II type 1 receptor)
Cozaar®	Cozaar®	Teva Pharmaceuticals USA	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (angiotensin II type 1 receptor)
Low dose losartan	Low dose losartan	Baker Heart and Diabetes Institute	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (Angiotensin II type 1 receptor)
irbesartan and irbesartan-hydrochlorothiazide	irbesartan and irbesartan-hydrochlorothiazide	Sanofi	marketed	Angiotensin II receptor blocker (ARB) / Thiazide diuretic combination	AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter (thiazide target)
Placebo to Telmisartan	Placebo to Telmisartan	Novartis	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (Angiotensin II type 1 receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor blocker (ARB) class)

Chong Kun Dang Pharmaceutical · 2 drugs in this class
Baker Heart and Diabetes Institute · 2 drugs in this class
Boryung Pharmaceutical Co., Ltd · 2 drugs in this class
Lee's Pharmaceutical Limited · 2 drugs in this class
Bristol-Myers Squibb · 1 drug in this class
Guangdong Provincial People's Hospital · 1 drug in this class
Fifth Affiliated Hospital, Sun Yat-Sen University · 1 drug in this class
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · 1 drug in this class
Bayer · 1 drug in this class
Arbor Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Valsartan (-based therapy) arm — Competitive Intelligence Brief. https://druglandscape.com/ci/valsartan-based-therapy-arm. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing